Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Increases By 147.4%

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 14,100 shares, a growth of 147.4% from the June 30th total of 5,700 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average trading volume of 21,400 shares, the short-interest ratio is currently 0.7 days.

Indaptus Therapeutics Stock Performance

Shares of Indaptus Therapeutics stock traded up $0.03 during midday trading on Friday, hitting $2.06. The company had a trading volume of 7,310 shares, compared to its average volume of 8,011. The company has a 50 day moving average of $2.32 and a 200 day moving average of $2.15. Indaptus Therapeutics has a 52-week low of $1.56 and a 52-week high of $4.08.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.12. On average, equities research analysts predict that Indaptus Therapeutics will post -1.72 earnings per share for the current fiscal year.

Institutional Trading of Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned about 0.17% of Indaptus Therapeutics as of its most recent SEC filing. Institutional investors own 7.06% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Indaptus Therapeutics in a report on Monday, June 17th.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.